Therefore, comprehending the biology of multiple myeloma (MM) and identifying drug-resistance biomarkers, such as TXNDC5, are crucial research challenges that could aid in the development of personalized treatment [135,137,141]. The gene discussed is TXNDC5; the disease is Miyoshi myopathy.